Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers.

doi:10.1111/cts.12989

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers.

Clinical and translational science - 1 Jul 2021

Wang Xinwen, Her Lucy, Xiao Jingcheng, Shi Jian, Wu Audrey H, Bleske Barry E, Zhu Hao-Jie

Abstract excerpt

Trandolapril, an angiotensin-converting enzyme inhibitor prodrug, needs to be activated by carboxylesterase 1 (CES1) in the liver to exert its intended therapeutic effect. A previous in vitro study demonstrated that the CES1 genetic variant G143E (rs71647871) abolished CES1-mediated trandolapril activation in cells transfected with the variant. This study aimed to determine the effect of the G143E variant on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Angiotensin-Converting Enzyme Inhibitors

Share to Blood Pressure

Share to Carboxylic Ester Hydrolases

Share to Healthy Volunteers

Share to Indoles

Share to Pharmacogenomic Variants

Share to Prodrugs

Source

Open in PubMed Open full text

Identifiers

PMID: 33660934
DOI: 10.1111/cts.12989
PMCID: PMC8301577

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers.PMID 33660934Read ↗

CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors.Semantic proximity Read ↗

CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril.Semantic proximity Read ↗

Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril.Semantic proximity Read ↗

Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects.Semantic proximity Read ↗

Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation.Semantic proximity Read ↗

A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms.Semantic proximity Read ↗

Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators.Semantic proximity Read ↗

Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.Semantic proximity Read ↗

Major implications of single nucleotide polymorphisms in human carboxylesterase 1 on substrate bioavailability.Semantic proximity Read ↗

Pharmacogenetic study of CES1 gene and enalapril efficacy.Semantic proximity Read ↗

Carboxylesterase 1 genetic variability, expression and potential for drug-drug interactionsSemantic proximity Read ↗

Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.